FOLH1 and bone metastasis: Positron emission tomography (PET) using prostate-specific membrane antigen (PSMA)-based tracers has been shown to be superior in detecting metastatic sites compared with conventional imaging at primary staging and imaging in biochemical recurrence (BCR) after radical prostatectomy.10,11 Prostate-specific membrane antigen PET/computed tomography (CT) has demonstrated higher sensitivity and specificity than 99mTc-MDP bone scan in detecting bone metastasis.12 The superior diagnostic accuracy of PSMA PET/CT may result in an increased rate of detection of skull metastases of PCa.